Search Results for "Fungal"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Fungal. Results 21 to 30 of 67 total matches.
Caspofungin (Cancidas) For Aspergillosis
The Medical Letter on Drugs and Therapeutics • Jul 09, 2001 (Issue 1108)
in other fungal infections, particularly
deep Candida infections, and whether it would be more effective ...
Caspofungin acetate(Cancidas) is the first of a new class of antifungals, the echinocandins. It has been approved by the FDA for treatment of invasive aspergillosis in patients who fail to respond to or are unable to tolerate other antifungal drugs such as amphotericin B and itraconazole.
OTC Fluticasone Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
infection (thrush),
mucosal atrophy, and septal perforation have been
reported rarely. Intranasal fungal ...
The nasal spray formulation of the corticosteroid
fluticasone propionate is now available over the
counter (OTC) as Flonase Allergy Relief (GSK) in
the same strength as the prescription product
(Flonase, and generics) for patients ≥4 years old with
seasonal or perennial allergic rhinitis. It is the second
corticosteroid nasal spray to become available OTC;
triamcinolone acetonide (Nasacort Allergy 24HR) was
the first. Unlike prescription Flonase, the OTC product
is FDA-approved for reduction of ocular as well as
nasal symptoms. Brand-name prescription Flonase
has been...
Topical Sertaconazole (Ertaczo) -- Another Azole for Tinea Pedis
The Medical Letter on Drugs and Therapeutics • Jun 21, 2004 (Issue 1185)
other imidazole antifungals, sertaconazole
inhibits synthesis of ergosterol, an essential component of the fungal ...
Sertaconazole nitrate (Ertaczo - OrthoNeutrogena), an imidazole antifungal similar to clotrimazole and miconazole, has been approved by the FDA as a 2% cream for topical treatment of interdigital tinea pedis infection. It has been available in Europe for many years.
Cost of Topical Products for Tinea Pedis
The Medical Letter on Drugs and Therapeutics • May 03, 2010 (Issue 1337)
, an essential component
of fungal cell membranes. Allylamines are more active
in vitro than imidazoles against ...
A Medical Letter reader recently received a diagnosis of athlete’s foot and a prescription for Naftin gel, for which his pharmacy charged $145, and his insurance company required a $70 copay because this formulation was not included in its formulary. Do patients need to pay prices like these to treat tinea pedis?
Laser Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • Feb 18, 2013 (Issue 1410)
.
For further information call: 800-211-2769
Laser Treatment of Onychomycosis
Fungal infections ...
Fungal infections of the fingernails or toenails can persist
for months or years despite topical and systemic
antimicrobial therapy. The FDA has cleared several
short-pulse laser systems for treatment of this mainly
cosmetic disorder.
Safe Needles
The Medical Letter on Drugs and Therapeutics • Apr 05, 1991 (Issue 841)
immunodeficiency
virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann ...
Accidental needlesticks can lead to infection with hepatitis viruses, human immunodeficiency virus, and other blood-borne bacterial, viral, and fungal pathogens (DK Henderson et al, Ann Intern Med, 113:740, 1990). Re-capping used needles is the most frequent cause of needlestick injuries (J Jagger et al, N Engl J Med, 319:284, 1988; MH Becker et al, Am J Infect Control, 18:232, 1990).
Omidubicel (Omisirge) for Neutrophil Recovery Following Myeloablative Conditioning Therapy (online only)
The Medical Letter on Drugs and Therapeutics • May 29, 2023 (Issue 1677)
transplantation. Grade 2/3 bacterial or
grade 3 invasive fungal infections up to 100 days
post-transplantation ...
The FDA has approved omidubicel-onlv (Omisirge –
Gamida Cell), a nicotinamide-modified, allogeneic
hematopoietic progenitor cell therapy derived from
cord blood, to reduce the time to neutrophil recovery
and the risk of infection in patients ≥12 years old
with hematologic malignancies who will undergo
umbilical cord blood transplantation following
myeloablative conditioning therapy. Hematopoietic
progenitor cell (HPC) umbilical cord products (e.g.,
Allocord, Clevecord, Ducord) have been available in
the US for years for the same indication. Cord blood
banks also supply cord...
Med Lett Drugs Ther. 2023 May 29;65(1677):e93-4 doi:10.58347/tml.2023.1677h | Show Introduction Hide Introduction
Golimumab (Simponi) for Inflammatory Arthritis
The Medical Letter on Drugs and Therapeutics • Jul 13, 2009 (Issue 1316)
fungal infections, and other opportunistic infections. The FDA has
reported that invasive fungal ...
Golimumab (Simponi - Centocor), a fully humanized anti-tumor necrosis factor (TNF)-a antibody, has been approved by the FDA for the treatment of: (1) moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate; (2) active psoriatic arthritis (PsA) alone or in combination with methotrexate; and (3) active ankylosing spondylitis (AS).
Oteseconazole (Vivjoa) for Recurrent Vulvovaginal Candidiasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
,
oteseconazole inhibits the fungal sterol 14α-
demethylase (CYP51). This enzyme catalyzes an
early step ...
The FDA has approved oteseconazole (Vivjoa –
Mycovia), a new oral azole antifungal, to reduce the incidence
of recurrent vulvovaginal candidiasis (RVVC)
in females with a history of RVVC. Oteseconazole is
the first drug to be approved in the US specifically for
treatment of RVVC.
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
infections.
INVASIVE CANDIDA INFECTIONS ― Candida spp. are
the most frequent cause of fungal diseases ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for
once-weekly treatment of candidemia and invasive
candidiasis (IC) in adults with limited or no alternative
options. It is the first new drug to become available
in the US in more than 15 years for treatment of
systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4 doi:10.58347/tml.2024.1705d | Show Introduction Hide Introduction